

### BFGFR, CD331

Catalog # PVGS1398

**Specification** 

## **BFGFR, CD331 - Product Information**

Primary Accession
Species
Human

P11362, P01857

#### Sequence

RPSPTLPEQA QPWGAPVEVE SFLVHPGDLL QLRCRLRDDV QSINWLRDGV QLAESNRTRI TGEEVEVQDS VPADSGLYAC VTSSPSGSDT TYFSVNVSDA LPSSEDDDDD DDSSSEEKET DNTKPNPVAP YWTSPEKMEK KLHAVPAAKT VKFKCPSSGT PNPTLRWLKN GKEFKPDHRI GGYKVRYATW SIIMDSVVPS DKGNYTCIVE NEYGSINHTY QLDVVERSPH RPILQAGLPA NKTVALGSNV EFMCKVYSDP QPHIQWLKHI EVNGSKIGPD NLPYVQILKT AGVNTTDKEM EVLHLRNVSF EDAGEYTCLA GNSIGLSHHS AWLTVLEALE ERPAVMTSPL YLEGSGSGSG SPKSCDKTHT CPPCPAPELL GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK

#### **Purity**

> 95% by SDS-PAGE and HPLC analyses.

### **Endotoxin Level**

< 0.2 EU/  $\mu$ g, determined by LAL method.

Formulation

Lyophilized after extensive dialysis against PBS.

#### Reconstitution

Reconstituted in ddH<sub>2</sub>0 at 100 μg/mL.

## **BFGFR, CD331 - Additional Information**

#### **Target Background**

<b>Fibroblast Growth Factor Receptor-1 (FGFR-1)
/b> is a transmembrane tyrosine kinase receptor belonging to the FGFR family. FGFR family has 4 members, FGFR-1 to FGFR-4, and they all have similar structural characteristics with 3 extracellular immunoglobulin-like (Ig) domains. FGFRs bind to FGFs with the second and third Ig domains, and complex with heparin sulfate when binding. The binding to FGF induces the dimerziation of FGFR and the phosphorylations of the intracellular tyrosines. Furthermore, the phosphorylated FGFR activates downstream signaling pathways, including STAT/JAK, RAS/MAPK, and PI3 K/AKT. Particularly, the signaling of FGFR-1 is stronger than that of FGFR-2, and sustains longer than that of FGFR-1 is involved in the breast cancer: the patients with the FGFR-1 amplification are more likely to develop distant metastases, and the amplification of FGFR-1 is significantly associated with a shorter overall survival. <br/>
bracecombinant <br/>
bracecombinant <br/>
bracecombinant <br/>
bracecombinant <br/>
bracecombinant <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly associated with a shorter overall survival. <br/>
bracecombinant significantly significantly associated with a shorter overall survival. <br/>
bracecombinant significantly significantly associated with a shorter overall survival. <br/>
bracecombinant significantly significantly significantly significantly significantly significantly significantly significa



# **BFGFR, CD331 - Protein Information**

# **BFGFR, CD331 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

BFGFR, CD331 - Images